IDL has signed a distribution agreement in Malaysia Read the press release here
Distribution agreement signed in Malaysia
read more
News
Latest news.
IDL Biotech har tecknat avtal för automatisering av tumörmarkören TPS®
Kina har i många år varit ledande i användningen av tumörmarkörer. IDL Biotech har nu tecknat avtal med det kinesiska företaget ZECEN Biotech som avser en automatisering av analysprocessen för tumörmarkören TPS® på ZECEN Biotechs instrument. TPS® är en tumörmarkör som...
Meta analysis on TUBEX
Achieving accurate laboratory diagnosis of typhoid fever: a review and meta-analysis of TUBEX® TF clinical performance. Read the article here: Read the press release here:
IDL signs distribution agreement in Uganda
IDL has signed a new distribution agreement in Uganda Read the press release here
IDL signed two new distributions agreements
IDL has signed two new distributions agreements. Please read the press release here (Asia) and here (Kenya)
IDL Biotech licensierar sin produktlinje för tumörmarkörer på den manuella plattformen radioimmunoassay till Beckman Coulter Diagnostics
IDL Biotech meddelar att de har tecknat ett avtal med Beckman Coulter om licensiering av IDL Biotechs samtliga tumörmarkörer på den manuella plattformen radioimmunoassay (IRMA). Licensavtalet ger Beckman Coulter globala försäljningsrättigheter och möjliggör för IDL...
IDL Biotech AB continues preparations to introduce its rapid test for bladder cancer, UBC Rapid, in the US.
IDL Biotech has started the work on mapping the US market. Read more here
IDL Biotech launches TUBEX TF in Kenya
On September 17, 2019, IDL Biotech will launch the company's rapid test for typhoid fever, TUBEX TF, in Kenya. Read more here
IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA
IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer. Read the press release here (in swedish)
Abstract shows the value of UBC Rapid
An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer. Read the press release here (in swedish)
